Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Biote Corp Market Cap
Based on ratings from 0 stock analysts, the Biote Corp stock price is expected to increase by 55.18% in 12 months. This is calculated by using the average 12-month stock price forecast for Biote Corp. The lowest target is $7 and the highest is $12. Please note analyst price targets are not guaranteed and could be missed completely.
Biote Corp has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Biote Corp will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of BTMD.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| George Kelly Roth MKM | Buy | $9 | Reiterates | Mar 13, 2024 |
| Jeff Van Sinderen B. Riley Securities | Buy | $9 | Initiates | Feb 20, 2024 |
| Kaumil Gajrawala Jefferies | Buy | $6.55 | Initiates | Feb 1, 2024 |
| Gregory Fraser Truist Securities | Buy | $9 | Maintains | Jan 18, 2024 |
| George Kelly Roth MKM | Buy | $7 | Maintains | Jan 18, 2024 |
| Brian Holland TD Cowen | Outperform | $7 | Maintains | Aug 15, 2023 |
| George Kelly Roth MKM | Buy | $12 | Reiterates | Aug 14, 2023 |
| George Kelly Roth MKM | Buy | $11 | Maintains | Mar 30, 2023 |
| Gregory Fraser Truist Securities | Buy | $10 | Initiates | Sep 27, 2022 |
| Brian Holland Cowen & Co. | Outperform | $11 | Initiates | Jun 24, 2022 |
| George Kelly Roth Capital | Buy | $9 | Initiates | Jun 23, 2022 |
When did it IPO
N/A
Staff Count
194
Country
United States
Sector/Industry
Healthcare/Medical Care Facilities
CEO
Ms. Teresa S. Weber
Market Cap
$323.7M
In 2023, BTMD generated $185.4M in revenue, which was a increase of 12.37% from the previous year. This can be seen as a signal that BTMD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Sat, 10 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - biote Corp. (NASDAQ:BTMD ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Szymon Serowiecki – Investor Relations Terry Weber – Chief Executive Officer Bob Peterson – Chief Financial Officer Conference Call Participants Les Sulewski – Truist Securities Jonna Kim – TD Cowen Richard Magnusen – B. Riley Securities George Kelly – ROTH Capital Kaumil Gajrawala – Jefferies Operator Good day, and welcome to the Biote Second Quarter 2024 Earnings Conference Call.
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $49.2 million Procedure revenue of $38.4 million Gross profit margin of 68.9%, including a $1.2 millio.
Thu, 08 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Cash indicates a company's true financial health. It is the key to its existence, development and success.
Thu, 25 Jul 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide second quarter financial results on Thursday, August 8, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may.
Thu, 25 Jul 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - biote Corp. (BTMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Wed, 24 Jul 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Achieving profit is, no doubt, a company's goal, but having a healthy cash flow is imperative to its existence, development and success. So, ASC, TXO, GPRK and BTMD are worth buying.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
